Pharmacoeconomics of drug therapy for rheumatoid arthritis

Rheumatology

Volumn 39, Issue SUPPL. 1, 2000, Pages 43-47

  Tugwell, P ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cost effectiveness; DMARDs; Pharmacoeconomics; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; ETANERCEPT; GOLD SALT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

CHRONIC INFLAMMATION; CLINICAL TRIAL; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DEATH; DRUG COST; DRUG EFFICACY; DRUG MONITORING; HEALTH CARE COST; HUMAN; METHODOLOGY; MORTALITY; PHYSICAL DISABILITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRODUCTIVITY; RHEUMATOID ARTHRITIS; SIDE EFFECT;

EID: 0034044350     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.rheumatology.a031494     Document Type: Conference Paper

References (26)

1. Wolfe F, Cathey MA. The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol 1991;18:1298-306.
2. Wolfe F, Mitchell DM, Sibley JT et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
3. Lawrence RC, Helmick CG, Arnett FC et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41:778-99.
4. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713-22.
5. Callahan LF. The burden of rheumatoid arthritis: facts and figures. J Rheumatol 1998;25(suppl. 53):8-12.
6. Yelin E, Callahan LF. The economic cost and social and psychological impact of musculoskeletal conditions. Arthritis Rheum 1995;38:1351-62.
7. McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol 1996;35:781-90.
8. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis. The impact of poor function and functional decline. Arthritis Rheum 1999;42:1209-18.
9. Kobelt G, Eberhardt K, Jönsson L, Jönsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-56.
10. Clarke AE, Zowall H, Levinton C et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 1997;24:1051-60.
11. Van Jaarsveld CHM, Jacobs JWG, Schrijvers AJP, Heurkens AHM, Haanen HCM, Bijlsma JWJ. Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study. Br J Rheumatol 1998;37:837-47.
12. Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Direct medical costs unique to people with arthritis. J Rheumatol 1997;24:719-25.
13. Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol 1997;24:43-8.
14. Prashker M, Meenan RF. The total cost of drug therapy for rheumatoid arthritis: a model based on costs of drug, monitoring, and toxicity. Arthritis Rheum 1995; 38:318-25.
15. Lambert CM, Hurst NP. Health economics as an aspect of health outcome: basic principles and application in rheumatoid arthritis. Br J Rheumatol 1995;34:774-80.
16. Ruchlin HS, Elkin EB, Paget SA. Assessing cost-effectiveness analyses in rheumatoid arthritis and osteoarthritis. Arthritis Care Res 1997;10:413-21.
17. Gabriel S, Tugwell P, O'Brien B et al. Report of the OMERACT task force on economic evaluation. J Rheumatol 1999;26:203-6.
18. Hannonen P, Mottonen T, Hakola M, Oka M. Sulfasalazine in early rheumatoid arthritis. Arthritis Rheum 1993;36: 1501-9.
19. Forre Ø, Norwegian Arthritis Study Group. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Arthritis Rheum 1994;37:1506-12.
20. Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999;353:259-66.
21. Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate. Arch Intern Med 1999;159:2542-50.
22. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
23. Anis AH, Tugwell PX, Wells GA, Stewart DG. A cost effectiveness analysis of cyclosporine in rheumatoid arthritis. J Rheumatol 1996;23:609-16.
24. Verhoeven AC, Bibo JC, Boers M, Engel GL, van der Linden SJ. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. Br J Rheumatol 1998;37:1102-9.
25. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
26. Kavanaugh A, Heudebert G, Cush J, Jain R. Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model. Semin Arthritis Rheum 1996;25:297-307.